Merit Medical Systems

Merit Medical Systems, Inc. engages in the manufacture and marketing of proprietary disposable medical devices. It operates through the Cardiovascular and Endoscopy segments. The Cardiovascular segment consists of peripheral intervention, cardiac intervention, interventional oncology and spine, and cardiovascular and critical care product groups. The Endoscopy segment integrates non-vascular stent technology with balloon dilators, inflation devices, guide wires, procedure kits, and other devices that are used by gastroenterologists, endoscopists, pulmonologists, and thoracic and general surgeons. The company was founded by Fred P. Lampropoulos, Darla Gill, Kent W. Stanger, and William Padilla in July 1987 and is headquartered in South Jordan, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merit Medical Systems reports robust Q4 performance and eyes growth

Merit Medical Systems delivered a strong Q4 performance with revenue growth, increased gross profit, and exceeding net income expectations.
While facing challenges in certain segments and regulatory compliance, the company remains optimistic about growth opportunities and operational improvements.
Strategic pricing initiatives and a focus on achieving financial targets position Merit Medical for continued success and potential expansion through M&A activities.
The company's commitment to discipline, prioritization, and operational excellence underscores its resilience and potential for sustained growth in the future.

Merit Medical Systems posts strong Q1 results, eyes debt reduction

Merit Medical Systems delivered robust financial results in Q1 2023, showcasing growth in revenue, operating income, and net income. The company maintains its financial guidance for 2023, emphasizing a commitment to debt reduction and free cash flow targets. Analyst inquiries highlighted areas for improvement and strategic focus moving forward.

Merit Medical Systems reports robust Q2 earnings amidst strategic acquisitions

Merit Medical Systems delivered strong financial performance in Q2 2023, marked by revenue growth, improved profitability, and strategic acquisitions. While facing challenges in the Endoscopy segment and uncertainties in international markets, the company remains focused on leveraging opportunities in catch-up procedures and strategic M&A for sustainable growth.

Merit Medical Systems excels in Q3, eyes growth opportunities

Merit Medical Systems delivered a strong Q3 performance with notable revenue growth, profit increases, and enhanced net income and EPS.
While facing challenges like margin pressure and regional headwinds, the company remains focused on long-term growth strategies and operational efficiency.
With opportunities for revenue expansion, product advancements, and margin improvements on the horizon, Merit Medical Systems is poised for continued success and shareholder value creation.

Merit Medical Systems excels in Q4 2023, eyes strategic growth

Merit Medical Systems delivered strong financial results in Q4 2023, driven by revenue growth and margin expansion.
The company's strategic initiatives and focus on operational efficiency position it well for future growth and profitability.
Challenges such as SKU rationalization and China revenue decline require careful management and strategic planning.
Opportunities in M&A, pricing power initiatives, R&D investments, and gross margin expansion strategies offer avenues for continued success.

Merit Medical Systems excels in Q1, eyes growth opportunities

Merit Medical Systems delivered strong Q1 results with revenue growth and profitability improvements, driven by operational progress and strategic focus on innovation.
While facing challenges such as pricing pressures in China and debt reduction strategies, the company remains poised for growth through new opportunities and market strategies.
With a solid performance in Q1 and positive Q2 guidance, Merit Medical Systems demonstrates resilience and a strategic approach to navigating industry challenges.
The company's commitment to financial stability, innovation, and shareholder value sets a strong foundation for future growth and market competitiveness.

Merit Medical Systems reports robust Q3 results amidst supply challenges

Merit Medical Systems delivered strong financial results in Q3, driven by revenue growth and margin improvement.
The company's strategic acquisition and focus on innovation position it well for future growth despite supply chain disruptions.
Challenges in supply chain management and analyst inquiries highlight areas for ongoing attention and improvement.
Overall, Merit Medical Systems maintains a positive outlook on its performance and growth trajectory.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SOUTH JORDAN, Utah, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today outlined the ongoing succession planning process for its Chief Executive Officer (CEO). Pursuant to an Amended and Restated Employment Agreement, effective June 8, 2023, Merit founder, CEO, and President, Fred Lampropoulos, will continue to serve as Merit's CEO and President through December 31, 2025.

Merit Medical Announces Process for Chief Executive Officer Succession Planning

Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.

Why You Should Retain Merit Medical (MMSI) Stock for Now

SOUTH JORDAN, Utah, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (Nasdaq: MMSI) (“Merit”), a leading global manufacturer and marketer of healthcare technology, announced the pricing of $650.0 million aggregate principal amount of 3.00% Convertible Senior Notes due 2029 (the “notes”) in a private placement (the “offering”) only to persons reasonably believed to be “qualified institutional buyers” pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Merit has granted the initial purchasers of the notes an option to purchase, during a 13-day period beginning on, and including, the date on which the notes are first issued, up to an additional $97.5 million aggregate principal amount of the notes on the same terms and conditions. The offering was upsized from the previously announced offering of $550 million aggregate principal amount of notes. The sale of the notes to the initial purchasers is expected to close on December 8, 2023, subject to customary closing conditions.

Merit Medical Announces Pricing of Upsized Private Offering of $650.0 Million of 3.00% Convertible Senior Notes Due 2029

SOUTH JORDAN, Utah, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (Nasdaq: MMSI) (“Merit”), a leading global manufacturer and marketer of healthcare technology, announced today that it intends to offer, subject to market conditions and other factors, $550.0 million aggregate principal amount of Convertible Senior Notes due 2029 (the “notes”) in a private placement (the “offering”) only to persons reasonably believed to be “qualified institutional buyers” pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Merit also intends to grant the initial purchasers of the notes an option to purchase, during a 13-day period beginning on, and including, the date on which the notes are first issued, up to an additional $82.5 million aggregate principal amount of the notes.

Merit Medical Announces Proposed Private Placement of $550 Million of Convertible Senior Notes

Patterson Companies

Investors looking for stocks in the Medical - Dental Supplies sector might want to consider either Patterson Cos. (PDCO) or Merit Medical (MMSI).

PDCO or MMSI: Which Is the Better Value Stock Right Now?

The mean of analysts' price targets for Merit Medical (MMSI) points to a 25.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

How Much Upside is Left in Merit Medical (MMSI)? Wall Street Analysts Think 25.31%

Merit Medical delivered another quarter ahead of expectations, with strong growth in peripheral intervention, OEM manufacturing, and endoscopy, driving 7% organic revenue growth coupled with opex leverage. Assets acquired from AngioDynamics are already outperforming initial expectations, and performance in several peripheral and cardiac markets suggests share gains. The pivotal study for the Wrapsody endovascular graft is complete and Merit should be in a position to launch the product before the end of 2024.

Merit Medical Caught Up In The Med-Tech Downswing

PDCO vs. MMSI: Which Stock Is the Better Value Option?

Merit Medical (MMSI) benefits from revenue growth in both segments and all product categories within its Cardiovascular unit in the third quarter.

Merit Medical (MMSI) Q3 Earnings Top Estimates, FY23 View Revised

Merit Medical Systems, Inc. (NASDAQ:MMSI ) Q3 2023 Earnings Conference Call October 26, 2023 5:00 PM ET Company Participants Fred Lampropoulos – Founder, Chairman and Chief Executive Officer Brian Lloyd – Chief Legal Officer and Corporate Secretary Raul Parra – Chief Financial Officer and Treasurer Conference Call Participants Michael Petusky – Barrington Research Steve Lichtman – Oppenheimer & Co Jayson Bedford – Raymond James Zachary Day – Canaccord Genuity Jim Sidoti – Sidoti & Co Mike Matson – Needham and Company Operator Welcome to the Third Quarter of Fiscal Year 2023 Earnings Conference Call for Merit Medical Systems, Inc. At this time, all participants have been placed in listen-only mode. After the speakers' presentation, there will be a question-and-answer session.

Merit Medical Systems, Inc. (MMSI) Q3 2023 Earnings Call Transcript

Although the revenue and EPS for Merit Medical (MMSI) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Merit Medical (MMSI) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Merit Medical (MMSI) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.65 per share. This compares to earnings of $0.64 per share a year ago.

Merit Medical (MMSI) Beats Q3 Earnings and Revenue Estimates

*  Constant currency revenue; constant currency revenue, organic; non-GAAP EPS; non-GAAP net income; non-GAAP operating income and margin; non-GAAP gross profit and margin; and free cash flow are non-GAAP financial measures. A reconciliation of these financial measures to their most directly comparable GAAP financial measures is included under the heading “Non-GAAP Financial Measures” below.

Merit Medical Reports Results for Third Quarter Ended September 30, 2023

Merit Medical's (MMSI) latest addition to its Vascular portfolio is expected to significantly improve patient outcomes.

Merit Medical's (MMSI) New Launch to Expand Its Product Suite

Henry Schein

Investors interested in Medical - Dental Supplies stocks are likely familiar with Henry Schein (HSIC) and Merit Medical (MMSI). But which of these two stocks offers value investors a better bang for their buck right now?

HSIC vs. MMSI: Which Stock Is the Better Value Option?

New multipurpose microcatheter length complements Merit's radial-first legacy New multipurpose microcatheter length complements Merit's radial-first legacy

Merit Medical Launches Expanded Maestro® Microcatheter Line

3 Reasons to Add Merit Medical (MMSI) Stock to Your Portfolio

SOUTH JORDAN, Utah, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended September 30, 2023, after the close of the stock market on Thursday, October 26, 2023.

Merit Medical Systems to Announce Third Quarter 2023 Results on October 26, 2023

Merit Medical (MMSI) launches Aspira Bottle, complementing its Aspira Drainage System, that can provide compassionate home treatment option for critical cancer and other patients.

Merit Medical's (MMSI) Aspira Bottle to Boost At-Home Services

Advanced design complements comprehensive drainage portfolio, expanding compassionate at-home treatment options to more patients Advanced design complements comprehensive drainage portfolio, expanding compassionate at-home treatment options to more patients

Merit Medical Launches the Aspira® Evacuated Drainage Bottle

Reasons to Retain Merit Medical (MMSI) Stock in Your Portfolio

Merit Medical (MMSI) is evaluating its device for treating stenosis/occlusion, WRAPSODY, in a pivotal study on patients undergoing hemodialysis. Primary data from the study is expected after six months.

Merit Medical (MMSI) Completes Enrollment in WRAPSODY Study

SOUTH JORDAN, Utah, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, today announced the completion of enrollment in its WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal study. Merit's WAVE study is a prospective, randomized, controlled, multicenter study comparing the Merit WRAPSODY Cell-Impermeable Endoprosthesis (CIE) to percutaneous transluminal angioplasty for treatment of stenosis/occlusion in the venous outflow circuit in patients undergoing hemodialysis.

Merit Medical's WRAPSODY™ Arteriovenous Access Efficacy (WAVE) Pivotal Study Completes Enrollment

Merit Medical (MMSI) benefits from revenue growth in both segments and all product categories within its Cardiovascular unit in the second quarter.

Merit Medical (MMSI) Q2 Earnings & Revenues Beat Estimates

Merit Medical Systems, Inc. (NASDAQ:MMSI ) Q2 2023 Earnings Conference Call July 25, 2023 5:00 AM ET Company Participants Fred Lampropoulos - Chairman and Chief Executive Officer Raul Parra - Chief Financial Officer Brian Lloyd - Chief Legal Officer and Corporate Secretary Conference Call Participants Steve Lichtman - Oppenheimer & Company Jayson Bedford - Raymond James Larry Biegelsen - Wells Fargo Jason Bednar - Piper Sandler Mike Matson - Needham & Company Jim Sidoti - Sidoti & Company Michael Petusky - Barrington Research Operator Welcome to the Second Quarter of Fiscal Year 2023 Earnings Conference Call for Merit Medical Systems, Inc. [Operator Instructions] Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly. I would now like to turn the call over to Mr.

News for Merit Medical Systems Stock (MMSI)